Format

Send to

Choose Destination
Br J Haematol. 2017 Jul;178(1):32-47. doi: 10.1111/bjh.14615. Epub 2017 May 5.

How I manage patients with Fanconi anaemia.

Author information

1
Haematology Unit, G. Gaslini Children's Research Hospital, Genova, Italy.
2
Chairman Severe Aplastic Anemia Working Party, EBMT.

Abstract

Fanconi Anaemia is a rare, genetic heterogeneous multisystem disease that is the most common congenital syndrome of marrow failure. Twenty genes have been reported to cause the disease. Remarkable progress has been made over the last 20 years in the understanding of the genetic and pathophysiological mechanisms. Unfortunately, these advances have not been completely paralleled by advances in medical treatment, where the most important component remains stem cell transplantation. This therapy, although contributing to long-term negative effects, such as increased occurrence of late malignancies, is the only current option capable of prolonging the survival of patients. In spite of relevant recent progress in matched unrelated donor transplants, the largest studies with longer follow-up still show a superiority of matched sibling donor transplants with a success rate, in selected cohorts, of over 90%. This article reviews different aspects of the disease, including genetics, diagnosis and treatment options, with special focus on stem cell transplantation, comprehensive post-diagnosis management, decision-making processes and long-term follow-up.

KEYWORDS:

Fanconi anaemia; overall management; transplant; treatment

PMID:
28474441
DOI:
10.1111/bjh.14615
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center